Skip to main content
HR 413 113th Congress House Health Digestive and metabolic diseases Drug therapy Health care coverage and access Medicaid Prescription drugs

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

Introduced: January 23, 2013 Introduced by: Welch, Peter Democratic · Vermont See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 8, 2013
Referred to the Subcommittee on Health.
Jan 25, 2013
Referred to the Subcommittee on Health.
Jan 23, 2013
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 23, 2013
Introduced in House
 Plain-English summary Congressional Research Service

Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)

What's happening now February 8, 2013

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4